5-FU metabolism in cancer and orally-administrable 5-FU drugs

Cancers

Volumn 2, Issue 3, 2010, Pages 1717-1730

  Miura, Koh ^a   Kinouchi, Makoto ^a   Ishida, Kazuyuki ^b   Fujibuchi, Wataru ^c   Naitoh, Takeshi ^a   Ogawa, Hitoshi ^a   Ando, Toshinori ^a   Yazaki, Nobuki ^a   Watanabe, Kazuhiro ^a   Haneda, Sho ^a   Shibata, Chikashi ^a   Sasaki, Iwao ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

5 FU metabolism; Cell death; Colon cancer; Oral 5 FU drugs

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; FLUOROURACIL; OXIDOREDUCTASE INHIBITOR; RO 0094889; TEGAFUR; UFT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL DEATH; COLON CANCER; CONTINUOUS INFUSION; DNA SYNTHESIS INHIBITION; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; NEUROTOXICITY; NONHUMAN; REVIEW; TISSUE DISTRIBUTION;

EID: 79952255682     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2031717     Document Type: Review

References (51)

1. Heidelberger, C.; Chaudhuri, N.K.; Danneberg, P.; Mooren, D.; Griesbach, L.; Duschinsky, R.; Schnitzer, R.J.; Pleven, E.; Scheiner, J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957, 179, 663-666.
2. Rutman, R.J.; Cantarow, A.; Paschkis, K.E. The catabolism of uracil in vivo and in vitro. J. Biol. Chem. 1954, 210, 321-329.
3. Handschumacher, R.E.; Welch, A.D. Microbial studies of 6-azauracil, an antagonist of uracil. Cancer Res. 1956, 16, 965-969.
4. Skipper, H.E.; Schabel, F.M. Jr.; Wilcox, W.S. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother. Rep. 1964, 35, 1-111.
5. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 1998, 16, 301-308.
6. Saif, M.W.; Syrigos, K.N.; Katirtzoglou, N.A. S-1: A promising new oral fluoropyrimidine derivative. Expert Opin. Investig. Drugs 2009, 18, 335-348.
7. Wohlhueter, R.M.; McIvor, R.S.; Plagemann, P.G. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J. Cell. Physiol. 1980, 104, 309-319.
8. Longley, D.B.; Harkin, D.P.; Johnston, P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3, 330-338.
9. Houghton, J.A.; Houghton, P.J.; Wooten, R.S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res. 1979, 39, 2406-2413.
10. Schuetz, J.D.; Wallace, H.J.; Diasio, R.B. 5-fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res. 1984, 44, 1358-1363.
11. Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol. 1998, 16, 3537-3541.
12. Diasio, R.B.; Harris, B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 1989, 16, 215-237.
13. Heggie, G.D.; Sommadossi, J.P.; Cross, D.S.; Huster, W.J.; Diasio, R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987, 47, 2203-2206.
14. Koenig, H.; Patel, A. Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch. Neurol. 1970, 23, 155-160.
15. Okeda, R.; Shibutani, M.; Matsuo, T.; Kuroiwa, T.; Shimokawa, R.; Tajima, T. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine. Acta Neuropathol. 1990, 81, 66-73.
16. Matsubara, I.; Kamiya, J.; Imai, S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn. J. Pharmacol. 1980, 30, 871-879.
17. Santi, D.V.; McHenry, C.S. 5-Fluoro-2'-deoxyuridylate: covalent complex with thymidylate synthetase. Proc. Natl. Acad. Sci. USA 1972, 69, 1855-1857.
18. Jackson, R.C.; Grindley, G.B. The biochemical basis for methotrexate cytotoxicity. In Folate Antagonists as Therapeutic Agents, 2nd edition; Sirotnak, F.M., Burchell, J.J., Ensminger, W.D., Eds.; Academic Press: New York, NY, USA, 1984; Volume 1, pp. 289-315.
19. Yoshioka, A.; Tanaka, S.; Hiraoka, O.; Koyama, Y.; Hirota, Y.; Ayusawa, D.; Seno, T.; Garrett, C.; Wataya, Y. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J. Biol. Chem. 1987, 262, 8235-8241.
20. Mitrovski, B.; Pressacco, J.; Mandelbaum, S.; Erlichman, C. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells. Cancer Chemother. Pharmacol. 1994, 35, 109-114.
21. Grem, J.L.; Fischer, P.H. Enhancement of 5-fluorouracil's anticancer activity by dipyridamole. Pharmacol. Ther. 1989, 40, 349-371.
22. Showalter, S.L.; Showalter, T.N.; Witkiewicz, A.; Havens, R.; Kennedy, E.P.; Hucl, T.; Kern, S.E.; Yeo, C.J.; Brody, J.R. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol. Ther. 2008, 7, 986-994.
23. Lembersky, B.C.; Wieand, H.S.; Petrelli, N.J.; O'Connell, M.J.; Colangelo, L.H.; Smith, R.E.; Seay, T.E.; Giguere, J.K.; Marshall, M.E.; Jacobs, A.D.; et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J. Clin. Oncol. 2006, 24, 2059-2064.
24. Boku, N.; Yamamoto, S.; Fukuda, H.; Shirao, K.; Doi, T.; Sawaki, A.; Koizumi, W.; Saito, H.; Yamaguchi, K.; Takiuchi, H.; et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol. 2009, 10, 1063-1069.
25. Mansfield, P.F.; Hohn, D.C.; Fornage, B.D.; Gregurich, M.A.; Ota, D.M. Complications and failures of subclavian-vein catheterization. N. Engl. J. Med. 1994, 331, 1735-1738.
26. Agnelli, G.; Verso, M. Therapy Insight: venous-catheter-related thrombosis in cancer patients. Nat. Clin. Pract. Oncol. 2006, 3, 214-222.
27. Lokich, J.J.; Moore, C.L.; Anderson, N.R. Comparison of costs for infusion versus bolus chemotherapy administration-Part two. Use of charges versus reimbursement for cost basis. Cancer 1996, 78, 300-303.
28. Giller, S.A.; Zhuk, R.A.; Lidak, M.Iu. Analogs of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolities. Dokl. Akad. Nauk. SSSR. 1967, 176, 332-335 (article in Russian).
29. Toide, H.; Akiyoshi, H.; Minato, Y.; Okuda, H.; Fujii, S. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann 1977, 68, 553-560.
30. Fujii, S.; Ikenaka, K.; Fukushima, M.; Shirasaka, T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 1978, 69, 763-772.
31. El Sayed, Y.M.; Sadée, W. Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes. Cancer Res. 1983, 43, 4039-4044.
32. Rustum, Y.M. Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology 1997, 54 (Suppl. 1), 7-11.
33. Diasio, R.B. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 1998, 12, 23-27.
34. Fujii, S.; Kitano, S.; Ikenaka, K.; Shirasaka, T. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5- fluorouracil in rodents. Gann 1979, 70, 209-214.
35. Hoff, P.M.; Cassidy, J.; Schmoll, H.J. The evolution of fluoropyrimidine therapy: From intravenous to oral. Oncologist 2001, 6 (Suppl. 4), 3-11.
36. Poon, M.A.; O'Connell, M.J.; Wieand, H.S.; Krook, J.E.; Gerstner, J.B.; Tschetter, L.K.; Levitt, R.; Kardinal, C.G.; Mailliard, J.A. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol. 1991, 9, 1967-1972.
37. Ichikura, T.; Tomimatsu, S.; Okusa, Y.; Yahara, T.; Uefuji, K.; Tamakuma, S. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Cancer Chemother. Pharmacol. 1996, 38, 401-405.
38. Cook, A.F.; Holman, M.J.; Kramer, M.J.; Trown, P.W. Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides. J. Med. Chem. 1979, 22, 1330-1335.
39. Ishitsuka, H.; Miwa, M.; Takemoto, K.; Fukuoka, K.; Itoga, A.; Maruyama, HB. Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine. Gann 1980, 71, 112-123.
40. Shirasaka, T.; Shimamato, Y.; Ohshimo, H.; Yamaguchi, M.; Kato, T.; Yonekura, K.; Fukushima, M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996, 7, 548-557.
41. Tatsumi, K.; Fukushima, M.; Shirasaka, T.; Fujii, S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn. J. Cancer Res. 1987, 78, 748-755.
42. Shirasaka, T.; Shimamoto, Y.; Fukushima, M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993, 53, 4004-4009.
43. Muneoka, K.; Shirai, Y.; Yokoyama, N.; Wakai, T.; Hatakeyama, K. 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. Int. J. Clin. Oncol. 2005, 10, 441-443.
44. Miwa, M.; Ura, M.; Nishida, M.; Sawada, N.; Ishikawa, T.; Mori, K.; Shimma, N.; Umeda, I.; Ishitsuka, H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5- fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 1998, 34, 1274-1281.
45. Shimma, N.; Umeda, I.; Arasaki, M.; Murasaki, C.; Masubuchi, K.; Kohchi, Y.; Miwa, M.; Ura, M.; Sawada, N.; Tahara, H.; et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg. Med. Chem. 2000, 8, 1697-1706.
46. Ishikawa, T.; Utoh, M.; Sawada, N.; Nishida, M.; Fukase, Y.; Sekiguchi, F.; Ishitsuka, H. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol. 1998, 55, 1091-1097.
47. Yen-Revollo, J.L.; Goldberg, R.M.; McLeod, H.L. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin. Cancer Res. 2008, 14, 8-13.
48. Milano, G.; Etienne-Grimaldi, M.C.; Mari, M.; Lassalle, S.; Formento, J.L.; Francoual, M.; Lacour, J.P.; Hofman, P. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br. J. Clin. Pharmacol. 2008, 66, 88-95.
49. Hattori, K.; Kohchi, Y.; Oikawa, N.; Suda, H.; Ura, M.; Ishikawa, T.; Miwa, M.; Endoh, M.; Eda, H.; Tanimura, H.; et al. Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine. Bioorg. Med. Chem. Lett. 2003, 13, 867-872.
50. Lee, J.L.; Kang, Y.K.; Kang, H.J.; Lee, K.H.; Zang, D.Y.; Ryoo, B.Y.; Kim, J.G.; Park, S.R.; Kang, W.K.; Shin, D.B.; et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br. J. Cancer 2008, 99, 584-590.
51. Seol, Y.M.; Song, M.K.; Choi, Y.J.; Kim, G.H.; Shin, H.J.; Song, G.A.; Chung, J.S.; Cho, G.J. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study. Jpn. J. Clin. Oncol. 2009, 39, 43-48.